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ABSTRACT
Therapeutic applications of microRNAs (miRNAs) in RAS-driven glioma were 
valuable, but their specific roles and functions have yet to be fully elucidated. Here, 
we firstly report that miR-143 directly targets the neuroblastoma RAS viral oncogene 
homolog (N-RAS) and functions as a tumor-suppressor in glioma. Overexpression 
of miR-143 decreased the expression of N-RAS, inhibited PI3K/AKT, MAPK/ERK 
signaling, and attenuated the accumulation of p65 in nucleus of glioma cells. In 
human clinical specimens, miR-143 was downregulated where an adverse with N-RAS 
expression was observed. Furthermore, overexpression of miR-143 decreased glioma 
cell migration, invasion, tube formation and slowed tumor growth and angiogenesis 
in a manner associated with N-RAS downregulation in vitro and in vivo. Finally, miR-
143 also sensitizes glioma cells to temozolomide (TMZ),the first-line drug for glioma 
treatment. Taken together, for the first time, our results demonstrate that miR-
143 plays a significant role in inactivating the RAS signaling pathway through the 
inhibition of N-RAS, which may provide a novel therapeutic strategy for treatment of 
glioma and other RAS-driven cancers.
INTRODUCTION
Glioma, the most common and aggressive form of 
primary brain tumor, presents a dismal prognosis. The 
poor prognosis and high lethality of the disease is largely 
due to the highly invasive/migratory nature of glioma 
cells, which are capable of diffusely infiltrating and widely 
migrating in the surrounding brain tissue [1-7]. Despite 
treating with combinations of surgery, radiotherapy and 
chemotherapy, glioblastomamultiforme (GBM), the most 
malignant and most common glioma, is associated with 
an average life expectancy as short as only 15 months [8]. 
Temozolomide (TMZ), a DNA alkylating antineoplastic 
drug, has been used universally in glioma treatment by 
inhibiting the proliferation of glioma cells and inducing 
apoptosis [9]. However, the patients′response rate to TMZ-
based chemotherapy still remains modest, mainly due to 
the development of drug resistance. Thus, it is essential to 
developing novel and effective therapeutic strategies for 
glioma.
MicroRNAs are small noncoding regulatory RNA 
molecules, with profound impact on a wide array of 
biological processes [10, 11]. MicroRNAs have been 
recently implicated in the regulation of tumorigenesis, 
differentiation, proliferation, and survival through the 
inhibition of major cellular pathways [12, 13]. Among 
them, miR-143 has been demonstrated to function as a 
tumor suppressor, and loss of miR-143 expression has 
been reported in many cancer types, restoration of miR-
143 expression has been shown to abrogate tumorigenesis 
Oncotarget5417www.impactjournals.com/oncotarget
[14]. To date, some genes have been identified as miR-
143 target genes, including K-RAS, ELK1, MYO6, Bcl-2 
, ERK5 and IGF-IR ,that are involved in pathogenesis of 
cancers [15-21]. However, the molecular mechanism of 
miR-143 repression in glioma has not been determined. 
RAS sarcoma (Ras) genes are the most frequently 
activated oncogenes in human cancer. K-RAS, N-RAS 
and H-RAS represent the prototype members of a family 
of small G proteins that are frequently activated to an 
oncogenic state in a wide variety of human tumors, 
including glioma. K-RAS has been reported to be a target 
of miR-143 in colorectal cancer cell. N-RAS, as one of the 
three members of the RAS oncogene family, encode small 
GTPases that are involved in cellular signal transduction. 
N-RAS is implicated and functionally altered in a number 
of cancers including glioma and has potential roles in 
the regulation of cancer cell growth, survival, migration, 
invasion, and angiogenesis [22, 23]. Enhanced expression 
of N-RAS gene by disorder of transcription may be a 
factor in the progression of glioma [24]. Oncogenic 
N-RAS promotes tumorigenesis through activation of 
multiple downstream pathways, including PI3K/AKT, 
MAPK/ERK, and NF-κB pathway [25-28]. Thus, N-RAS 
silencing has become an efficient therapeutic strategy in 
glioma, but it is still far from optimal and novel therapeutic 
strategies are needed urgently.
In the present study, we demonstrated that miR-143 
was downregulated in human glioma. Then, we will ask 
several important questions in this study: (1) what are the 
roles of miR-143 in tumor growth and angiogenesis; (2) 
what is the potential direct target of miR-143 that may be 
associated with cancer development; and (3) whether miR-
143 overexpression inhibits AKT, ERK1/2, and NF-κB 
signaling pathways via its direct target; (4) What role of 
miR-143 and underlying mechanisms in glioma resistance 
to TMZ treatment. The answers of these questions would 
provide new insights into the molecular mechanism of 
glioma development as well as provide new therapeutic 
strategy for glioma treatment in the future.
RESULTS
MiR-143 expression was downregulated in glioma
To investigate the role of miR-143 in glioma, we 
first evaluated the expression levels of miR-143 in normal 
brain tissues and glioma tissues by qRT-PCR (Figure 1A). 
The results showed that the expression levels of miR-
143 were consistently lower in the glioma tissues than 
in normal brain tissues. By dividing all glioma samples 
into Grade II, Grade III, and Grade IV according to 
WHO classification, we found that miR-143 levels were 
downregulated in these 3 groups compared to the normal 
brain group. But the levels of miR-143 expression among 
high grade tumors (WHO Grades III and IV) showed 
no significantly difference to those in low grade tumors 
(WHO Grade II) (Figure 1B). Our results indicated that the 
loss of miR-143 might be an early event in gliomagenesis.
N-RAS is a direct target of miR-143
To fully understand the mechanisms of miR-143 in 
glioma, TargetScan search program was used to predict 
targets of miR-143, which N-RAS has been thought to 
be putative target of miR-143 (Figure 2A). U87 cells 
were cotransfected with the wild (WT) or mutated (Mut) 
N-RAS luciferase reporter vector together with miR-143 
or miR-NC for 24 h, and luciferase activities in those 
cells were measured. As shown in Figure 2B, luciferase 
activities were significantly reduced in those cells 
transfected with the wild sequence and miR-143, but not 
in the cells with the mutant sequence and miR-143. Then, 
Western blotting analysis was conducted to measure the 
Figure1: MiR-143 expression was downregulated in glioma.(A)Relative miR-143 expression levels were analyzed by qRT-PCR 
in 6 normal brain tissues and 24 glioma tissues. U6 RNA level was used as an internal control. (B) The levels of miR-143 expression in 
normal brain tissues and three different grades of glioma samples. According to the pathological classification, the 24 glioma tissues were 
divided into three groups (8 glioma tissues each group): WHO Grade II, Grade III and Grade IV. Data represent mean±SD of 3 replicates. 
** indicated significant difference at P<0.01. 
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levels of N-RAS protein, we found that the expression of 
N-RAS protein was downregulated in miR-143 treated 
cells, but increased in cells transfected with anti-miR-143 
inhibitor (Figure 2C). These results suggest that miR-143 
directly targets N-RAS by binding its seed region to their 
3’-UTRs in glioma cells.
Furthermore, we measured the levels of N-RAS 
protein in glioma specimens and normal brain tissues. 
The results showed that the average expression levels of 
N-RAS were significantly higher in tumor tissues than 
those in the normal brain tissues (Figure 2D). Then, we 
determine the correlation between N-RAS levels and 
miR-143 expression levels in the same glioma tissues. As 
shown in Figure 2E, Spearman’s rank correlation analysis 
showed that the expression levels of N-RAS and miR-
143 in 24 glioma specimens were inversely correlated 
(Spearman’s correlation r=-0.4757). 
MiR-143 inhibits AKT and ERK1/2 pathways as 
well as the expression of HIF-1α and VEGF via 
targeting N-RAS
The AKT and ERK1/2 pathways act as major 
downstream of RAS signaling, and several downstream 
factors such as hypoxia-inducible factor 1α (HIF-1α) and 
vascular endothelial growth factor (VEGF) have been 
linked to the AKT and ERK1/2 pathway. Cellular levels 
of p-AKT and p-ERK1/2 were significantly decreased in 
U87 and U251 cells stably expressing miR-143 compared 
with miR-NC, while no statistically significant reduction 
of AKT and ERK1/2 was detected (Figure 3A). 
Previous studies have shown the importance of HIF-
1α and VEGF in the regulation of angiogenesis in glioma 
[29, 30]. Here, we observed that HIF-1α and VEGF levels 
in miR-143-expressing U87 and U251 cells were both 
downregulated (Figure 3A and B). It has been reported 
that HIF-1α activates the expression of VEGF gene by 
binding to the hypoxia response element (HRE) in the 
VEGF promoter region. To determine whether miR-143 
inhibits VEGF expression through HIF-1α DNA binding 
site of VEGF promoter, we analyzed the effects of miR-
143 on a pMAP11WT VEGF promoter reporter plasmid 
containing the HIF-1α binding site, and a pMAP11Mut 
plasmid which 3 bp substitution at the HIF-1α binding 
site. As shown in Figure 3C, miR-143 inhibited the 
pMAP11WT reporter activity in U87 and U251 cells, but 
not pMAP11Mut reporter activity, which indicating that 
miR-143 inhibits the expression of VEGF through HIF-1α. 
To further explore whether the overexpression of N-RAS 
influence the expression of p-AKT, p-ERK1/2, HIF-1α 
and VEGF, U87 cells were cotransfected with or without 
Figure2: N-RAS is a direct target of miR-143. (A)Sequence of the miR-143-binding site within the human N-RAS 3′-UTR and a 
schematic diagram of the reporter construct showing the entire N-RAS 3′-UTR sequence and the mutated N-RAS 3′-UTR sequence. The 
mutated nucleotides of the N-RAS 3′-UTR are labeled in red. (B)Luciferase assay on U87 cells, which were co-transfected with miR-NC 
or miR-143 and a luciferase reporter containing the full length of N-RAS 3′-UTR (WT) or a mutant(Mut) in which four nucleotides of the 
miR-143-binding site were mutated. Activities were measured 24 hours post transfection. MiR-143 markedly suppressed luciferase activity 
in N-RAS3′-UTR (WT) reporter constructs. The data are means ± SEM for separate transfections (n=4). (C)The immunoblotting showed 
that expression levels of N-RAS were decreased in cells with miR-143 overexpression, but increased in cells with anti-miR-143 inhibitor. 
(D)The expression levels of N-RAS in normal human brain tissues and glioma specimens were determined by Western blotting analysis, 
and fold changes were obtained from the ratio of N-RAS to GAPDH levels. (E)Spearman′s correlation analysis was used to determine the 
correlation between the expression levels of N-RAS and miR-143 in human glioma specimens. Data represent mean±SD of 3 replicates. *, 
** indicated significantly different at P<0.05, P<0.01, respectively.
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pCMV6-N-RAS cDNA, these data provide evidence that 
miR-143 inhibits AKT and ERK1/2 pathways as well as 
the expression of HIF-1α and VEGF via targeting N-RAS 
(Figure 3D and E). 
MiR-143 attenuates the accumulation of p65 in 
nuclear in glioma cells
Constitutive overactivation of NF-κ B signaling is a 
common event in human cancers and acts as a key factor 
in cancer development and progression [31-35]. Then, 
we examined whether miR-143 affects NF-κB pathway. 
As shown in Figure 4A, the luciferase activity of the 
Figure3: MiR-143 inhibits AKT and ERK1/2 pathways as well as the expression of HIF-1α and VEGF via targeting 
N-RAS. (A) The expression levels of phosphorylated AKT (p-AKT), phosphorylated ERK1/2 (p-ERK1/2) and HIF-1α were decreased in 
cells with miR-143 overexpression detected by immunoblotting, while AKT and ERK1/2 protein levels were not changed. (B) VEGF levels 
were measured by qRT-PCR in miR-NC and miR-143 stable cell lines and normalized to level of GAPDH. (C) VEGF reporter plasmid 
pMAP11-WT or pMAP11-mut was cotransfected with pRL-TK plasmid and equal amounts of miR-NC, miR-143. Firefly and Renilla 
luciferase activities were measured 24 h later. (D) Overexpression of N-RAS restored miR-143-inhibited levels of p-AKT,p-ERK1/2 and 
HIF-1α. (E) Overexpression of N-RAS rescued VEGF mRNA expression inhibited by miR-143. The VEGF mRNA levels were normalized 
to that of GAPDH. Data represent mean±SD of 3 replicates. *indicates significant difference compared to control, #indicates significant 
difference compared to miR-143 treatment alone at P<0.05.
Figure4: MiR-143 attenuates the accumulation of p65 in nucleus in glioma cells. (A) Luciferase assay of the interaction 
between NF-κB signaling and miR-143 in U87 cells. Immunoblotting analysis of IKKα, IκBα, p65 and GAPDH in U87/miR-NC and U87/
miR-143 cells. (B)Immunoblotting analysis of p65, GAPDH in cytoplasmic extracts (Cyto) and p65, Histone 3 in nuclear extracts (NE) 
in U87/miR-NC,U87/miR-143,and U87/miR-143 overexpressed with N-RAS. (C) Immunofluoresence assay was performed on U87/miR-
NC,U87/miR-143,and U87/miR-143 overexpressed with N-RAS. MiR-143 attenuated the accumulation of p65 in nucleus in glioma cells. 
Overexpression of N-RAS rescued the accumulation of p65 in nucleus inhibited by miR-143. Data represent mean±SD of 3 replicates. 
*indicate significantly different at P<0.05. p65: Red; DAPI: Blue; Merge: Blue+Red.
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NF-κB reporter decreased in miR-143-overexpression 
cells, suggesting that miR-143 contributes to NF-κB 
inactivation. MiR-143 overexpression led to reduced 
phosphorylation of IKKα and elevated IκBα, but the 
expression of p65, a member of NF-κB family did not 
changed in U87/miR-143 cells. However, the expression 
levels of p65 were higher in cytoplasmic extracts of miR-
143-overexpressing stable cell lines than in miR-NC cells, 
while expression of p65 were lower in nuclear extracts; 
more interestingly, overexpression of N-RAS rescued 
the accumulation of p65 in nucleus inhibited by miR-143 
(Figure 4B). Similarly, we found the expression levels 
of p65 in miR-143-overexpressing stable cell lines were 
lower than that of miR-NC group associated with N-RAS 
group in nucleus by immunofluorescence stain, which 
indicated that miR-143 may attenuate the accumulation 
of p65 in nucleus in an N-RAS dependent manner (Figure 
4C). Taken together, these results further support the 
notion that miR-143 functions as a tumor suppressor in 
glioma and inhibits NF-κB signaling pathway in vitro by 
targeting N-RAS. 
Figure5: Overexpression of N-RAS reverses the inhibitory effects of miR-143.(A) Overexpression of miR-143 arrested cell 
proliferation, but this was rescued upon coexpression of exogenous N-RAS in U87 cells. (B) Cells were treated as above. A sterile 200 
μl pipette tip was used to scratch the cells to form a wound. The wound gaps were photographed (top) and measured (bottom). Forced 
expression of miR-143 also markedly reduced the wound-healing rate, and overexpression of N-RAS reverses the inhibitory effects of 
miR-143. (C) miR-143 overexpression decreased cell invasion in U87 cells. Cells were transfected with miR-143 followed by N-RAS 
transfection. All cells were subjected to a Matrigel invasion assay. Scale bar, 20 μm. (D)Representative images and quantification of 
HUVECs cultured on Matrigel-coated plates with conditioned medium from the indicated cells. Scale bar, 20 μm. Data represent mean±SD 
of 3 replicates. *indicates significant difference compared to control, #indicates significant difference compared to miR-143 treatment alone 
at P<0.05.
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Figure7: MiR-143 inhibits tumor growth and angiogenesis in vivo. (A, B,C) Effect of miR-143 on the growth of U87 cells 
inoculated into nude mice. Male BALB/c nude mice were subcutaneously injected with 5x106 U87 cells infected with lentiviruses harboring 
miR-NC or miR-143. Tumor volume and weight were monitored over time as indicated, and the tumor was excised and weighed after 
24 days. MiR-143 overexpression causes a decrease in tumor volume and weight. Bar=1mm. (D) The expression levels of downstream 
pathway proteins from the tumor tissues of miR-143 expressing group were lower than that of miR-NC group by immunoblotting assay. (E) 
The expression levels of VEGF and CD31 were analyzed in tumor tissues by immunohistochemistry with representative images showed. 
The density of VEGF protein levels was analyzed by qRT-PCR, and CD31 levels were quantified by ImageJ software. Magnification, 
×200,Scale bar, 20 μm. Data were presented by mean±SD. *indicated P<0.05.
Figure6: Overexpression of miR-143 increases chemosensitivity of glioma cells to TMZ by inhibiting its target N-RAS. 
(A)U87 cells stably expressing miR-NC or miR-143 were pretreated with various concentration of TMZ for 48 h, and subjected to CCK8 
Assay. (B) U87 cells stably expressing miR-NC, miR-143 or miR-143 forced expression of N-RAS were pretreated with 100 μM of TMZ 
for indicated time points, then subjected to CCK8 Assay, apoptosis analysis by flow cytometry (C) and Western blotting (D). Data represent 
mean±SD of 3 replicates. *indicates significant difference compared to control, #indicates significant difference compared to miR-143 
treatment alone at P<0.01.
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Overexpression of miR-143 suppresses 
cell proliferation, migration, invasion,and 
angiogenesis in vitro
Given the important role of N-RAS in regulation of 
cell proliferation, migration and invasion [36, 37], miR-
143-overexpressing U87 cells were used to analyze cell 
growth and invasion. The results showed that cell growth 
and migration were attenuated in miR-143-overexpressing 
U87 cells compared with U87 cells expressing miR-NC 
(Figure 5A and B). We showed that forced expression of 
N-RAS restored miR-143-inhibited cell proliferation and 
migration (Figure 5A and B).
Since invasion and angiogenesis are key 
characteristics of malignant tumor, we next investigated 
the effects of miR-143 on invasion and angiogenesis in 
vitro. Restoration of miR-143 dramatically inhibited the 
normally strong invasive capacity of U87 cells (Figure 
5C). Simultaneously, tube formation assay showed that 
miR-143-transfected group HUVECs presented less tube 
length, indicating angiogenesis was suppressed (Figure 
5D). As expected, forced expression of N-RAS reversed 
miR-143-mediated suppression of cell invasion and 
angiogenesis. Thus, our results suggest that overexpression 
of miR-143 suppresses glioma cell proliferation, 
migration, invasion and angiogenesis by inhibiting its 
target N-RAS. 
Overexpression of miR-143 increases 
chemosensitivity of glioma cells to TMZ by 
inhibiting its target N-RAS
Resistance to TMZ treatment is one of the major 
causes for the failure of chemotherapy in treating 
glioma. Therefore, it is critical to discover new strategies 
to increase the effectiveness of TMZ for therapeutic 
purposes. Our results showed that overexpression of miR-
143 in U87 cells significantly increased chemosensitivity 
to treatment of TMZ (Figure 6A). Furthermore, cell 
growth rate in the presence of TMZ (100μM) was assayed 
by CCK-8 proliferation assay at different time points, then 
forced expression of N-RAS reversed miR-143-induced 
glioma chemosentivity to TMZ (Figure 6B). To further 
study whether miR-143 and its target N-RAS play a role 
in cell apoptosis in the presence of TMZ treatment, FACS 
analysis was performed to detect cell apoptosis rates. The 
combination of miR-143 and TMZ treatment significantly 
induced cell apoptosis, whereas forced expression of 
N-RAS partially abolished the effect induced by miR-143 
plus TMZ treatment (Figure 6C). Similarly, we also found 
that the expression of N-RAS in U87/143 cells treated 
with TMZ is lower that the non-treated by immunobloting 
(Figure 6D). These results indicated that miR-143 renders 
glioma cells more sensitive to TMZ treatment, miR-143 
and TMZ combination induced apoptotic effect through 
targeting N-RAS in glioma cells. 
MiR-143 inhibits tumor growth and angiogenesis 
in vivo
In order to test whether miR-143 attenuates 
progression of glioma in vivo, we engineered U87 cells 
to stably express miR-NC or miR-143, which were 
subsequently implanted into both posterior flanks of 
immunodeficient mice, and tumor sizes were measured 
after 2 weeks. From the 2nd to 4th week, miR-NC-injected 
group developed significantly larger tumors than miR-
143 group (Figure 7A). MiR-143 stable-expressing cells 
generated xenografts that were statistically significantly 
smaller than control (Figure 7B). Meanwhile,the final 
tumor weight of miR-NC group was much heavier than 
miR-143 group (Figure 7C). In agreement with in vitro 
studies, the levels of N-RAS from the tumor tissues of 
miR-143 expressing group were lower than that of 
miR-NC group by immunoblotting assay (Figure 7D). 
Moreover, some downstream pathway proteins, such 
as p-AKT, p-ERK1/2 and HIF-1α were significantly 
suppressed by miR-143 in glioma tissues (Figure 7D). 
Consistent with our previous studies, we showed that miR-
143 inhibited tumor growth via anti-angiogenesis function. 
IHC staining revealed that the expression levels of VEGF 
and CD31 were significantly repressed by miR-143 
inglioma tissues (Figure 7E). It was also confirmed that 
VEGF expression in xenograft tumors were significantly 
decreased by miR-143. Furthermore, quantitative 
microvascular density (MVD) analysis showed significant 
suppression in miR-143 overexpression group, inferring 
that miR-143 represses angiogenesis in xenografts. Taken 
together, these results suggest that miR-143 inhibits tumor 
growth and angiogenesis in vivo through targeting N-RAS 
and other downstream signaling molecules.
DISCUSSION
MicroRNAs (miRNA), a novel class of regulatory 
molecules, have been frequently indicated to be 
dysregulated in diverse human cancers [38]. MiRNAs 
have been documented to function both as tumor 
suppressor genes and oncogenes, regulating many cellular 
events. Recent studies have been reported that miR-143 
plays a potential role as a tumor suppressor in many kinds 
of cancers [12, 13, 36]. However, there are no results 
referring to the role of miR-143 in glioma at present. In 
this study, we found that the expression of miR-143 is 
downregulated in glioma samples compared with normal 
brain tissues. Moreover, overexpression of miR-143 
significantly inhibited glioma cell migration, invasion, and 
tumor growth.
RAS family play a pivotal role in the transduction 
of several growth or differentiation factor stimuli [39]. It 
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has been reported that the expression levels of K-RAS 
and N-RAS are related to the malignant degree of cancers, 
including glioma, breast cancer, melanoma, and other 
cancers [40-43]. Recently, accumulating evidence has 
indicated that expression levels of the RAS family can 
be regulated by miRNAs. For example, overexpression 
of miR-145 can inhibits tumor angiogenesis and growth 
by targeting N-RAS and VEGF. It has been revealed 
that K-RAS gene is a target of miR-143 in colorectal 
cancer [17]. In our study, N-RAS oncogene has been 
experimentally validated as the novel target of miR-
143 not only in vitro, but also in vivo. Firstly, luciferase 
reporter assay confirmed that miR-143 directly recognize 
the 3′-UTR of N-RAS transcripts. Secondly, N-RAS 
expression was significantly abolished in glioma cells 
which miR-143 stablely-expressed andincreased in 
glioma cells which miR-143 inhibited. Thirdly, an 
inverse correlation between N-RAS protein and miR-
143 in clinical samples was found. Finally, inhibition 
of N-RAS expression by miR-143 inhibits constitutive 
phosphorylation of AKT and ERK1/2. Taken together, 
the present study provides the first evidence that miR-143 
is significant in suppressing glioma cell growth through 
inhibition of N-RAS translation.
Angiogenesis is a key process in gliomagenesis. 
AKT and ERK1/2 are upstream regulators of HIF-1α 
and VEGF, which are the important components for 
angiogenesis [44, 45]. Consistent with our previous 
study, phosphorylation of AKT (p-AKT) and ERK1/2 
(p-ERK1/2) was significantly inhibited by treatment with 
miR-143, therefore inhibited the expression of HIF-1α and 
VEGF; nevertheless, overexpression of N-RAS restored 
miR-143-inhibited cellular levels of p-AKT,p-ERK1/2, 
HIF-1α and VEGF. Here, we found that miR-143 functions 
as an anti-angiogenic regulator in gliomatumorigenesis. 
Overexpression of miR-143 in glioma cells led to reduced 
tube formation, number of microvessels in vivo, and then 
impaired tumor growth in tumor xenograft. Interestingly, 
we also found the interaction between NF-κB signaling 
pathway and miR-143 in indicated cells by reporter gene 
assay, immunoblotting and immunofluorescence stain 
in our study. These results indicate that miR-143 may 
attenuate the accumulation of p65 in nuclear by targeting 
N-RAS. Apparently, the precise mechanisms by which 
miR-143 inactivates NF-κB pathway in glioma need to be 
further investigated. Taken together, our study highlighted 
the key role of miR-143 in growth of glioma and suggested 
that miR-143 could be an ideal target for glioma therapy.
Despite having a better understanding of the 
molecular events that govern the glioma than ever before, 
it remains a clinical challenge in the treatment of glioma. 
Identification of new biomarkers that play a central role 
in the progression of glioma will benefit diagnosis and 
targeting therapy of the disease. MiRNAs are differentially 
expressed in chemosensitive and chemoresistant cells [46, 
47]. Several studies have suggested that miRNAs are 
novel players in the development of chemoresistance. 
Recent study showed that ectopic miR-34a sensitized 
the colorectal cancer cells to 5-fluorouracil [48]. MiR-
211 in combination with ionizing radiation (IR) and 
temozolomide significantly induces glioma cells apoptosis 
and DNA fragmentation [49]. In this study, we found that 
forced overexpression of miR-143 promoted the effects 
of TMZ. Flow Cytometer Assay demonstrated that U87 
cells with miR-143 stable expression have TMZ higher 
sensitiveness to apoptosis. Thus, it is important that a 
miR-143 restoration approach may offer a new modulation 
strategy to overcome chemoresistance to TMZ treatment 
in giloma.
In summary, we have identified a link between 
miR-143 and N-RAS that is a novel constituent of 
glioma tumorigenesis. Over the past few years, it has 
been shown that miR-145 and miR-124 target N-RAS 
in different tumors such as breast cancer, colon cancers 
and glioblastoma stem cells. We speculate that these 
tissue-specific miRNAs may contribute to the cognate 
abnormality via similar pathways. Now despite having 
a better understanding of the molecular events that 
govern the glioma than ever before, it remains a clinical 
challenge in the treatment of glioma. Identification of new 
biomarkers that play a central role in the progression of 
glioma will benefit diagnosis and targeting therapy of the 
disease.
MATERIALS AND METHODS
Human tissue samples
Human glioma samples and normal tissues were 
obtained from the Department of Neurosurgery, the First 
Affiliated Hospital of Nanjing Medical University. This 
study was approved by the hospital institutional review 
board and written informed consent was obtained from 
all patients. Tissue samples were collected at surgery, 
immediately frozen in liquid nitrogen and stored until total 
RNAs or proteins were extracted. 
Cell culture and reagents
Human glioma cell lines, U87 and U251 were 
maintained in DMEM medium with high glucose and 
sodium pyruvate, and human embryonic kidney 293T 
(HEK-293T) cells were cultured in DMEM medium, 
supplemented with 10% fetal bovine serum and antibiotics 
(100 units/ml penicillin and 100 mg/ml streptomycin). 
Cells were incubated at 37°C in a humidified atmosphere 
of 5% CO2 in air. Antibodies against p-AKT (Ser473), 
AKT, p-ERK1/2 and ERK1/2 were purchased from Cell 
Signaling Technology (Danvers, MA, USA). Antibodies 
against HIF-1α,Histone 3 and GAPDH were from 
Oncotarget5424www.impactjournals.com/oncotarget
Bioworld Technology (Atlanta, Georgia 30305, USA), and 
antibodies against N-RAS, p65, p-IKKα(Thr23) and IκBα 
were from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA), respectively. The growth factor reduced Matrigel 
were from BD Biosciences (Bedford, MA, USA).
Lentivirus packaging and stable cell lines
The lentiviral packaging kit was purchased from 
Open Biosystems (Huntsville, AL, USA). Lentivirus 
carrying hsa-miR-143 or hsa-miR-negative control 
(miR-NC) was packaged following the manufacturer’s 
manual. Lentivirus were packaged in HEK-293T cells 
and collected from the medium supernatant. Stable cell 
lines were established by infecting lentivirus into U87 and 
U251 cells and selected by puromycin.
RNA extraction, reverse transcription PCR and 
quantitative real time-PCR 
RNA was isolated from harvested cells or human 
tissues with Trizol reagent according to the manufacturer′s 
instruction (Invitrogen, CA, USA). To measure expression 
levels of miR-143, stem-loop specific primer method was 
used as described before [50, 51]. Expression of U6 was 
used as an endogenous control. To determine the mRNA 
levels of VEGF, total RNAs were reversely transcribed by 
oligodT primer using PrimeScript RT Reagent Kit (Takara, 
Dalian, China). Housekeeping gene GAPDH was used as 
internal control,primers were used as described before 
[15]. The cDNAs were amplified by qRT-PCR using 
SYBR Premix DimerEraser (Takara, Dalian, China) on 
a 7900HT system, and fold changes were calculated by 
relative quantification (2-△ △ Ct). 
Immunoblotting
Cells were washed with ice-cold PBS buffer, scraped 
from the dishes, and centrifuged at 12,000 rpm, 4°C for 
15 min. Cell lysates were prepared using RIPA buffer 
supplemented with protease inhibitors (100 mM Tris, pH 
7.4, 150 mMNaCl, 5mM EDTA, 1% Triton X-100, 1% 
deoxycholate acid, 0.1% SDS, 2mMphenylmethylsulfonyl 
fluoride, 1mM sodium orthovanadate, 2mM DTT, 
2mMleupeptin, 2mMpepstatin). The supernatants were 
collected and protein concentration was determined using 
BCA assay (Beyotime Institute of Biotechnology, Jiangsu, 
China). Tumor tissues from human and nude mice were 
grinded into powder in liquid nitrogen with RIPA buffer, 
and the total tissue proteins were extracted as described 
above. Aliquots of protein lysates were fractionated by 
SDS-PAGE, transferred to a PVDF membrane (Roche, 
Switzerland), and subjected to immunoblotting analysis 
according to the manufacturer′s instruction. ECL Detection 
System (Thermo Scientific, Rockford, IL, USA) was used 
for signal detection.
Luciferase reporter assay
The 3′-UTR of N-RAS were synthesized and 
annealed, then inserted into the SacI and HindIII sites of 
pMIR-reporter luciferase vector (Ambion) at downstream 
of the stop codon of the gene for luciferase. For its 
mutagenesis, the sequences complementary to the binding 
site of miR-143 in the 3′-UTR (N-RAS:TTCATCTC) was 
replaced by TACTTGAC. These constructs were validated 
by sequencing. U87 cells were seeded into a 24-well plate 
for luciferase assay. After cultured overnight, cells were 
cotransfected with the wild-type or mutated plasmid, pRL-
TK plasmid, and equal amounts of miR-143 or miR-NC. 
Luciferase assays were performed 24h after transfection 
using the Dual Luciferase Reporter Assay System 
(Promega, WI, USA). The primers are as follows: N-RAS 
forward primer:5′-GCGAGCTCGCTTCTTGTAATTCAT
CTCTGCTAA-3′, reverse primer:5′-GCAAGCTTTTATG
ACTAAGCCAAGAACTTCCAG-3′.
To determine the effects of miR-143 on 
transcriptional activation of VEGF, VEGF reporter 
plasmid pMAP11-WT or pMAP11-mut [52]was 
cotransfected into U87 cells with pRL-TK plasmid and 
equal amounts of miR-143 or miR-NC. Firefly and Renilla 
luciferase activities were measured 24h later. Experiments 
were performed in three independent replicates.
Cell proliferation 
To determine the effects of miR-143 on growth 
of glioma cells, cells were seeded in 96-well plates 
at confluence of 2000 cells per well. The absorptions 
of the cells were measured using a CCK8 kit (Dojindo 
Laboratories, Kumamoto, Japan) according to the 
manufacturer′s instruction at different indicated time 
points. Data were from three separate experiments with 
four replications each time.
Wound healing assay
Cells were cultured until reached 90% confluence 
in 6-well plates. Cell layers were scratched using a 20μ 
L tip to form wounded gaps, washed with PBS twice 
and cultured. The wounded gaps were photographed 
at different time points and analyzed by measuring the 
distance of migrating cells from five different areas for 
each wound.
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Cell invasion assay
Invasion assay was determined using 24-well BD 
Matrigel invasion chambers (BD Biosciences, Cowley, 
UK) in accordance with the manufacturer′s instructions. 
5×104 cells were seeded per well in the upper well of the 
invasion chamber in DMEM without serum, the lower 
chamber well contained DMEM supplemented with 10% 
FBS to stimulate cell invasion. After incubation for 24 h, 
noninvading cells were removed from the top well with 
a cotton swab while the bottom cells were fixed with 
3% paraformaldehyde, stained with 0.1% crystal violet, 
and photographed in three independent fields for each 
well. They were finally extracted with 33% acetic acid 
and detected quantitatively using a standard microplate 
reader (at 570 nm). Three independent experiments were 
conducted in triplicate.
Tube formation assay
To pretreat the 96-well plate, 50 μL of growth 
factor-reduced Matrigel thawed on ice was added to each 
well. The plate was then placed in an incubator to allow 
the gel to solidify at 37°C for 1 h. Cells were cultured to 
90–100% concentration, the old medium was discarded 
and provided with serum-reduced medium (1% FBS) 
for 24h. The medium was collected and stored at -80°C. 
HUVEC cells at subconcentration were switched to EBM-
2 basic medium containing 0.2% FBS. In 24 h, the starved 
HUVEC cells were trypsinized, collected, counted, and 
resuspended in EBM-2 basic medium. Then cells were 
mixed with equal volume of the conditioned medium and 
seeded to Matrigel-pretreated 96-well plate at 104cells/
well. In 12h, tube formation was examined under light 
microscope. The length of the tubes was measured using 
the Soft Imaging System (Soft Imaging System GmbH, 
Germany). 
In Vitro Chemosensitivity array
Cancer cells were seeded at a density of 4,000 cells 
per well in a 96-well plate overnight. Freshly prepared 
TMZ (Sigma-Aldrich, St. Louis, MO, USA) was added 
with the final concentration ranging from 12.5 to 600 μM. 
48h later, cell viability was assayed by CCK8 kit. 
Apoptosis Assay
Apoptosis were measured by flow cytometry 
as described before[53]. For AnnexinV staining, 5 μL 
phycoerythrin-Annexin V, 5 μL propidium iodide (BD 
Pharmingen) and 400μL 1 × binding buffer were added 
to the samples, which were incubated for 15 min at room 
temperature in the dark. Then the samples were analyzed 
by flow cytometry (FACS Canto II, BD Biosciences) 
within 1 h. The data were analyzed using FlowJo software. 
Three experiments were performed in triplicate.
Tumorigenesis in nude mice
Male BALB/c nude mice (6-weeks-old) were 
purchased from Shanghai Laboratory Animal Center 
(Chinese Academy of Sciences, Shanghai, China) and 
maintained in special pathogen-free (SPF) condition for 
one week. Animal handling and experimental procedures 
were in accordance with the Guide for the Care and Use 
of Laboratory Animals, and approved by the Animal 
Experimental Ethics Committee of Nanjing Medical 
University. U87 cells stably expressing miR-143 or miR-
NC were injected subcutaneously into both flanks of nude 
mice (5×106 cells in 100 µl). Tumor sizes were measured 
using vernier caliper every two days when the tumors 
were apparently seen and tumor volume was calculated 
according to the formula: volume = 0.5×Length×Width2. 
24 days after implantation, mice were sacrificed and 
tumors were dissected. Total proteins and RNAs were 
extracted for immunoblotting and qRT-PCR. Tumors were 
formalin-fixed, paraffin-embedded, and sectioned at 5µm 
for VEGF (Santa Cruz, CA, USA) and CD31 (Abcam, 
Cambridge, UK) immunohistochemical staining under the 
standard procedure as described before [54].
Statistical analysis
All experiments were performed three times and 
data were analyzed with GraphPad Prism 5 (La Jolla, 
CA, USA). The correlation between miR-143 expression 
and N-RAS levels in glioma tissues were analyzed using 
Spearman′s rank test. Statistical evaluation for data 
analysis was determined by t-test. The differences were 
considered to be statistically significant at P< 0.05.
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